Investigating a Whole Person Pain Assessment Approach in Relation to Nociception Functioning
PM&R · 2026-11 · 18 (S3)
DOI: 10.1002/pmrj.245_70259 ↗Kurz gefasst
Fachartikel in der Zeitschrift PM&R, online erschienen am 10.11.2026. Verfasst von Khashayar Rishsefid Mahalleh und 4 weiteren Autor:innen.
Themen: Schmerzmanagement
Abstract (Originalsprache)
practice) (Ongoing)jSPR Therapeutics: Research Grants (paid to self, institution or practice) (Ongoing)jStratus Medical: Research Grants (paid to self, institution or practice) (Ongoing).Background and/or Objectives: A recent randomized controlled trial (RESET Clinical Trial, n=222) met its primary endpoint, with significantly more participants treated with percutaneous 60-day peripheral nerve stimulation (60-day PNS; n=112) reporting ≥50% reductions in average low back pain compared to those treated with usual care with standard interventional management (e.g., physical therapy, injections, ablations; n=110) at 3 months [1].
Design
The present analysis examined the relationship between treatment delivery, baseline variables, and 60-day PNS outcomes in the RESET population cohort who underwent 60-day PNS (Group 1).
Setting
21 US clinical sites Participants: In Group 1, 91 participants completed the 3-month visit and 89 participants completed the 6-month visit.
Interventions
Group 1 underwent bilateral PNS lead implantation (SPRINT ® PNS System, SPR) targeting the lumbar medial branches for ≤60 days.Per protocol treatment delivery of 60-day PNS was defined as bilateral stimulation with usage of 6-12 hours per day and sensations that overlapped >50% of the painful area.Main Outcome Measures: Univariate regressions evaluated associations between clinical characteristics and responder rate (≥50% reduction in average pain at 3 months).Responder rates were reported for cohorts with facetogenic (clinical exam or ≥80% relief from a medial branch block) and discovertebral (clinical exam or findings on imaging) features.
Results
Participants with per protocol treatment delivery of 60-day PNS had 3.04 times higher odds of being a responder at 3 months (p=0.023).Baseline characteristics (age, pain duration, gender, average pain, pain interference, and disability) and response to a medial branch block did not significantly predict treatment response.Cohorts with facetogenic (69% responders; n=36) and discovertebral (68% responders; n=40) features were treatment responders.Reductions in pain extended to improvements in pain interference and disability through 6 months (follow-up ongoing).
Conclusions
Our findings suggest that per protocol treatment delivery of percutaneous 60-day PNS is an important determinant of treatment response, highlighting the importance of patient education, engagement, and adherence.
Zitieren
APA
Mahalleh, K. R., Axelrod, A., Amare, A., Mickle, A., & Sibille, K. T. (2026). Investigating a Whole Person Pain Assessment Approach in Relation to Nociception Functioning. PM&R, 18(S3). https://doi.org/10.1002/pmrj.245_70259
Vancouver
Mahalleh KR, Axelrod A, Amare A, Mickle A, Sibille KT. Investigating a Whole Person Pain Assessment Approach in Relation to Nociception Functioning. PM&R. 2026;18(S3). doi:10.1002/pmrj.245_70259
BibTeX
@article{Mahalleh2026,
author = {Mahalleh, Khashayar Rishsefid and Axelrod, Alyssa and Amare, Abenezer and Mickle, Angela and Sibille, Kimberly T.},
title = {Investigating a Whole Person Pain Assessment Approach in Relation to Nociception Functioning},
journal = {PM&R},
year = {2026},
volume = {18},
number = {S3},
doi = {10.1002/pmrj.245_70259}
}
EUVIMED